Scarica l'app Stockscreener
1.89
2.16%
0.04
Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie
Squarepoint Ops LLC Acquires Shares of 28,411 Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Millennium Management LLC Invests $462,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Inhibikase Therapeutics Insider Buyers Pleased With US$788k Return On Investment - simplywall.st
Inhibikase Therapeutics Reports Q1 2025 Financial Results - TipRanks
13,129 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Purchased by Stifel Financial Corp - Defense World
Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating - TipRanks
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase Therapeutics, Inc. SEC 10-Q Report - TradingView
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Reports $93M War Chest, Accelerates Revolutionary PAH Treatment Development - Stock Titan
Barclays PLC Purchases New Holdings in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Former Inhibikase leader launches new biotech for midstage Parkinson's asset - Fierce Biotech
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT) - PR Newswire
Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH - Seeking Alpha
Geode Capital Management LLC Purchases 272,813 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
IKTInhibikase Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
In wake of Anthos buyout, CFO McIntyre joins Inhibikase - biocentury.com
Inhibikase Therapeutics Advances PAH Treatment with New Leadership - TipRanks
Inhibikase Therapeutics appoints new CFO By Investing.com - Investing.com South Africa
Inhibikase Therapeutics Names David McIntyre as CFO - marketscreener.com
Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO - marketscreener.com
Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise - MSN
Inhibikase Therapeutics appoints new CFO - Investing.com Australia
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewswire
Strategic Hire: Venture Capital Veteran and Life Sciences CFO Expert Takes Helm at Inhibikase - Stock Titan
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
In the wake of Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) latest US$29m market cap drop, hedge funds owners may be forced to take severe actions - simplywall.st
Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses - Yahoo
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock - Investing.com India
HC Wainwright Reaffirms “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT) - Defense World
Inhibikase Therapeutics' (IKT) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Therapeutics Inc. (IKT) reports earnings - Quartz
Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth - Stock Titan
INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More - Nasdaq
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research
After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury
Inhibikase enhances leadership with new appointments By Investing.com - Investing.com Nigeria
Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewswire
Inhibikase Therapeutics, Inc. Announces Management Appointments -February 24, 2025 at 08:00 am EST - Marketscreener.com
Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals - TipRanks
Inhibikase enhances leadership with new appointments - Investing.com
Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):